Medicare officials are proposing to restrict coverage of a controversial Alzheimer's drug, Aduhelm, to participants in the federal health insurance program who are enrolled in qualifying clinical trials., the Centers for Medicare & Medicaid Services said Tuesday that it based its proposal on an analysis of the benefits and risks of the drug, which has raised concerns about Aduhelm's high cost and efficacy.
"While there may be the potential for promise with this treatment, there is also the potential for harm to patients," said Dr. Lee Fleisher, chief medical officer at CMS and director of the Center for Clinical Standards and Quality, in the statement."This harm may range from headaches, dizziness and falls, to other potentially serious complications such as brain bleeds."
The agency said will make a final decision on covering the drug by April 11. Medicare's decision on whether to pay for Aduhelm is important because it affects whether health insurers will cover the cost. The Food and Drug Administration approved Aduhelm last June, the first drug to cleared by government health officials for treating Alzheimer's in nearly two decades. But the treatment has also sparked criticism, with the FDA's outside panel of neurological experts
Source: Healthcare Press (healthcarepress.net)
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Reuters - 🏆 2. / 97 Read more »
Source: NBCNewsHealth - 🏆 707. / 51 Read more »
Source: KIRO7Seattle - 🏆 271. / 63 Read more »
Source: CNN - 🏆 4. / 95 Read more »
Source: PennLive - 🏆 463. / 53 Read more »
Source: NBCLA - 🏆 319. / 59 Read more »